Effectiveness of Prophylactic use of Etoricoxib in Comparison with Ibuprofen on Postendodontic Pain-randomized Double-Blind, Placebo-controlled Study: An in vivo Study

Abstract

Aim To determine if prophylactic etoricoxib significantly reduce postendodontic pain when compared with prophylactic ibuprofen and to establish if any relationship exists between pulpal and periapical diagnosis and the need for additional medication after completion of pulpectomy. Materials and methods Sixty patients consented to a double-blind, single-dose oral administration of 120 mg of etoricoxib or ibuprofen 600 mg or placebo before conventional root canal therapy. The patients were discharged with a VAS to fill out the intensity of pain initially first four hours every hour and then in 8, 12, 24, 48, and 72 hours after initial therapy. Each patient was given an escape envelope containing 650 mg of paracetamol in case of continued pain after taking the test medication in question. The patients were instructed to indicate in the VAS form if this additional medication was required and record the time it was taken. Results The result of the study showed that etoricoxib provided significantly better pain relief than placebo and ibuprofen. There was no statistically significant difference between placebo and ibuprofen. No difference in drug groups with respect to pulpal and periapical status was observed. Conclusion Prophylactic etoricoxib administration provides effective reduction of postendodontic pain. Furthermore, studies are required to know the pulpal and periapical status and need for additional medication.

Analgesia preemptiva com dexametasona ou ibuprofeno em tratamentos e retratamentos endodônticos com ampliação foraminal

“…A isoforma COX-1 é classificada como fisiológica, uma vez que está presente constitutivamente nos tecidos e é responsável pela produção de mediadores com função citoprotetora. Já a isoforma COX-2 é classificada como patológica, pois tem sua ação induzida na presença de injúria e inflamação, por estímulos como lipopolissacarídeo bacteriano (LPS) e citocinas pró-inflamatórias (interleucina 1 e 2 e fator de necrose tumoral) (Swapna et al, 2011;Vane et al, 1998).…”